Financial Reports
Related Searches:
Filter by:
361 - 375 of 676 results
October 29, 2009
Specialty pharmaceuticals sales were up 8% in the quarter to $940.6 million, while medical devices sales were down 11% to $187.2 million.
Read More »
October 28, 2009
Development segment revenue for the quarter was $315.8 million (-12%), and income from operations was $52.2 million (-25%).
Read More »
October 27, 2009
In the quarter, Global Specialty Injectables revenue was $575.7 million (+24%).
Read More »
October 23, 2009
Pharmaceutical sales in the quarter were $7.2 billion (+8%).
Read More »
October 22, 2009
Singulair sales were $1.1 billion in the quarter (+5%).
Read More »
October 22, 2009
Biopharmaceutical sales were $4.8 billion (+6%)
Read More »
October 22, 2009
Pharmaceutical sales in the quarter were $3.5 billion (+6%).
Read More »
October 22, 2009
Late-stage revenues were up 24%, but early-stage revenues were down 9% in 3Q09
Read More »
October 22, 2009
Product sales fell 1% in 3Q09 to $3.7 billion; U.S. sales were flat at $2.9 billion.
Read More »
October 20, 2009
Total pharmaceutical sales in the quarter were $10.7 billion (-3%).
Read More »
October 20, 2009
Growth in the quarter was driven primarily by Tysabri sales, up 21% to $207 million.
Read More »
October 14, 2009
Pharma revenues for 3Q09 were $4.1 billion, a 2% drop from last year.
Read More »
October 13, 2009
Worldwide pharmaceutical revenues dropped 14% to $5.2 billion in 3Q09
Read More »
361 - 375 of 676 results
